Articles On Cellmid (ASX:CDY)

The S&P/ASX200 is lower in late trade on Tuesday, dropping around 30 points or 0.4%, after iron ore futures plunged in Singapore. The SGX March booking shed a full 10% after lunch (Singapore time) on reports Beijing has just had it with...

2021 didn’t quite turn out way we’d hoped after the initial pandemic chaos on 2020. With the past 12 months throwing up even more curve balls than the year before, testing the resilience of many, we asked several startup founders what they...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Investment business HGL (HNG) has entered a trading halt while it plans a capital raise HGL hasn’t provided any indication as to how much it’s raising or how it will spend the money but, it has released its results for the 12 months ending...

Tech made up the majority of top stocks today but taking first place was investment company HGL (ASX:HNG). HGL (ASX:HNG) HGL is an investment company that owns or has owned a wide variety of assets from hatmaker Mountcastle – which began in...

In 2021 many COVID beneficiary stocks actually dropped following their financial results, as investors questioned the sustainability of their rapid growth rates. But that wasn’t the case with this morning’s cohort:   Dropsuite (ASX:DSE) Dro...

Highlights PointsBet has been appointed as Austin FC’s Exclusive Sportsbook Partner through an exclusive agreement. HGL and Cellmid Ltd. have signed a share sale agreement for its 100% owned subsidiary BLC Cosemtics’ merger with Cellmi...

The ASX 200 health stocks index (XHJ) has lifted by 0.46% at the time of writing, compared to the broader ASX 200 index which rose by 0.73%. Mergers and acquisitions were very much the order of the day in the Health sector today. The countr...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Summary The ASX 200 rebounded strongly from opening losses and reclaimed 7,400 levels. The market rally was driven by strong gains in technology, telecom, and healthcare stocks. BNPL player ZIP Co was the top performer on the ASX with...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

The health and beauty-tech business is focused on global distribution and sales of its scientifically validated innovative consumer products.

Summary The Vulcan Energy stock has shot up by 5.33% to AU$8.3 in today’ session. FCT’s quarterly update fails to impress investors as the share price has nosedived by 9.52% in today’s session. McPherson’s full year sales revenue is f...

Summary Neuren Pharmaceuticals obtained a Canadian patent grant for trofinetide, with a patent term that extends to January 2032. Health technology company Medibio Limited has secured a pre-submission meeting with the FDA for a new 510...

The company will retain the benefit of future upside with a 4% royalty on product sales by Lyramid (8% on sub-licence income).

The company has made progress in its new product development program with a hair loss supplement formulation completed and manufacturing and ecommerce set to launch during the first half of 2022.

The most intriguing big buy from a director last week came for forensic data company Nuix (ASX:NXL). Nuix was one of last year’s biggest IPOs and nearly doubled in the few weeks after its debut but then retreated in February after missing p...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Its lead manager and underwriter received bids from institutional and professional investors in excess of the available shortfall.

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Source:S_L, Shutterstock Summary Cellmid has announced a rights issue of $3.8 million. The company would be spending the proceeds to increase digital marketing activities to grow its subscriber base. Cellmid’s share price has fallen...

The FGF5 inhibitor aptamers add to the company’s proprietary anti-ageing hair care technologies and underpin Cellmid’s scientific leadership in the field.

Summary Cellmid Limited announced the first order from Chinese distributor and released its Q2 FY2021 highlighting improved Australian and US e-commerce performance. The significant order, coupled with improved cashflows and the ongoin...

ASX shares are tracking marginally higher at the half. On last Friday, the S&P 500 closed slightly lower, but NASDAQ made new highs as tech firms rose.  Investors expect a strong earnings season from the tech sector, which sent the US...

Summary The distribution agreement represents a significant development in the three-year growth strategy.  The Chinese market for hair growth products is growing enormously, especially for products with scientific backing and prove ef...

This is a transformational deal for Cellmid, as it completes the foundation of its China growth strategy.

The company is focused on growing revenue through shifting to e-commerce, increasing distribution channels across new geographies and increasing awareness of its brands of differentiated, clinically validated anti-ageing solutions.

As Cellmid will focus solely on its consumer health business following the divestment of its biotech assets, changes have been made to its board and senior management.

Favourable global trends in the consumer sector are expected to provide strong tailwinds to reach its sales objectives in the next 12-24 months.

Cellmid advised the market in February 2019 of its intention to separate its consumer health and biotech assets.

The company has focused on ecommerce channels during the COVID-19 pandemic for its range of evolis hair care products but has also found a new revenue stream in SARS-CoV-2 tests for medical practitioners.

Tru Beauty is a premium salon distributor and national educator servicing 40,000 salons in 11 states in the northeast of the USA.

COVID-19 has resulted in radical shifts in the health sector such as the adoption of tele-health, but the pandemic hasn’t been without financial impact. With the deadline for lodging 4C reports looming next Friday the first results trickled...

The agreement with IMD provides access to laboratory-based ELISA systems that can quantify the level and identify the type of antibodies against different SARS-CoV-2 antigens.

An exclusive distribution agreement between Australian life science company Cellmid (ASX: CDY) and Immunodiagnostics Limited, Hong Kong (IMD) will beef up the company's response to the COVID-19 crisis. The deal will see Cellmid acquire co...

Australian company Cellmid (ASX:CDY) has signed an exclusive distribution agreement with Hong Kong-based company Immunodiagnostics for laboratory-based, quantitative Enzyme-Linked Immunosorbent Assays (ELISA’s) and a point of care s...

The agreement for the distribution of the test has been extended until December 30, 2020.

The company is developing solutions to a range of conditions associated with ageing and inflammatory and autoimmune conditions.

In the last fortnight another two dozen directors of ASX small caps made trades above $100,000 and a number of them chipped into potash stocks. COVID-19 was the last thing potash stocks needed having been struggling prior to the pandemic. T...

The company is developing solutions to a range of conditions associated with ageing and inflammatory and autoimmune conditions.